Background: CXCR (CXC Chemokine Receptor) is a complex of the immune-associated protein involved in tumor activation, invasion, migration, and angiogenesis through various chemical signals in the tumor microenvironment (TME). However, significant prognostic characteristics of CXCR members and their impact on the occurrence and progression of glioma have not yet been fully elucidated.Methods: In this research, we used Oncomine, TCGA, GTEx, and CGGA databases to analyze the transcription and survival data of glioma patients. Afterward, the influence of CXCR members on the TME was explored using comprehensive bioinformatics analysis.Results: The mRNA expression levels of CXCR1/2/3/4/7 were significantly up-regulated in glioma than in normal samples, whereas the mRNA expression level of CXCR5 was decreased. We then summarized the genetic alteration landscape of CXCR and identified two molecular subtypes based on CXCR expression patterns in glioma. The characteristics of CXCRs were also investigated, including the clinicopathological parameters, TME cell infiltration, and prognosis of patients with glioma. After Lasso and multivariable Cox regression, a CR-Score for predicting overall survival (OS) was constructed and the predictive performance of the signature was validated. The high-risk group was a significantly poorer prognostic group than the low-risk group as judged by the CR-Score (TCGA cohort, p < 0.001, CGGA cohort, p < 0.001). Moreover, the CR-Score was significantly correlated to the tumor-immune infiltration and cancer stem cell (CSC) index. A risk scale-based nomogram incorporating clinical factors for individual risk estimation was established thereby.Conclusion: These findings may pave the way for enhancing our understanding of CXCR modification patterns and developing better immune therapeutic approaches for glioma.

Background Pyroptosis could regulate tumor cell trafficking, invasion, and metastasis, as well as tumor microenvironment (TME). However, prognostic characteristics of pyroptosis-related genes (PRGs) and their impact on the progression of glioma remain insufficient. Methods The genetic, transcriptional, and survival data of glioma patients used for bioinformatics analysis were obtained from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases. Results We first screened two different molecular subtypes and found that PRG variations were associated with the characteristics of TME cell infiltration, clinicopathological characteristics, and prognosis of patients with glioma. After Cox regression of differentially expressed genes, a risk-score for predicting overall survival (OS) and progression-free survival (PFS) was calculated and its predictive accuracy in glioma patients was then validated. The high-risk group of PRGs signature showed a significantly poor OS compared to the low-risk group (training cohort, p <0.001, validation cohort, p <0.001). A high risk-score implies more immune cell infiltration and a better immunotherapy response to immune checkpoint blockers. Furthermore, the risk-score was significantly associated with the chemotherapeutic drug sensitivity and cancer stem cell (CSC) index. Subsequently, we established a highly accurate nomogram to facilitate the applicability in the preliminary clinical application of the risk-score. Conclusion Our findings may lay the foundation for future research targeting pyroptosis in glioma and pave the way for evaluating prognosis and developing more effective immunotherapy strategies.